Showing 3681-3690 of 20437 results for "".
- Sex Differences in Mouse Brain GLP‑1 Mapping: Clinical Implicationshttps://reachmd.com/news/sex-differences-in-mouse-brain-glp1-mapping-clinical-implications/2485994/A recent report describes an RNAscope atlas of Glp1: a sex-specific
- In Relapsing MS, BTK Inhibitor Fenebrutinib Showed Reduced Relapse Rate vs Aubagiohttps://reachmd.com/news/in-relapsing-ms-btk-inhibitor-fenebrutinib-reduces-relapse-rate-vs-aubagio/2485955/Key Takeaways Results from the phase 3 FENhance 1 trial showed fenebrutinib reduced annualized relapse rate compared with Aubagio in people with relapsing multiple sclerosis. Combined results from FENhance 1 a
- Genotype‑Informed Nutrition in Obesity/Prediabeteshttps://reachmd.com/news/genotypeinformed-nutrition-in-obesityprediabetes/2485902/The systematic review Personalised Nutrition in Obesity and Prediabetes describes evidence for genotype-guided dietary response in adults with obesity or prediabetes as mixed across loci, endpoin
- Integrin αV–YAP–CTGF Signaling Links Congestion to Fibrosis and Cancerhttps://reachmd.com/news/integrin-vyapctgf-signaling-links-congestion-to-fibrosis-and-cancer/2485866/A Gastroenterology study used single-cell and spatial transcriptomic mapping in liver si
- Pooled ADORING Analysis: Tapinarof Linked to Early Sleep Improvements in Pediatric ADhttps://reachmd.com/news/pooled-adoring-analysis-tapinarof-linked-to-early-sleep-improvements-in-pediatric-ad/2485858/A pooled pediatric subanalysis from ADORING 1 and 2 was reported to show that once-daily
- Bictegravir–Ienacapavir Single-Tablet Switchhttps://reachmd.com/news/bictegravirienacapavir-single-tablet-switch/2485843/A phase 3 randomized evaluated a once-daily bictegravir–lenacapavir single-tablet regimen as a swi
- ECG screening in 14–35-Year-Olds: Yield, Interventions, and Repeat Checkshttps://reachmd.com/news/ecg-screening-in-1435-year-olds-yield-interventions-and-repeat-checks/2485833/A large ECG screening cohort of 14–35-year-olds is described in the CRY ECG screening cohort, with the report highlighting how often potentially serious conditions were detected, what
- REDEFINE 4: CagriSema 23% vs Tirzepatide 25.5% — Primary Non‑Inferiority Not Methttps://reachmd.com/news/redefine-4-cagrisema-23-vs-tirzepatide-255-primary-noninferiority-not-met/2485794/Novo Nordisk’s press release reports topline findings from REDEFINE 4, a he
- Medtronic Stealth AXiS: FDA-Cleared Integrated Planning, Navigation, and Roboticshttps://reachmd.com/news/medtronic-stealth-axis-fda-cleared-integrated-planning-navigation-and-robotics/2485761/Medtronic’s announcement reports U.S. FDA clearance for the
- Menstruation and Increased Vaso-Occlusive Pain in Females with Sickle Cell Diseasehttps://reachmd.com/news/menstruation-and-increased-vaso-occlusive-pain-in-females-with-sickle-cell-disease/2485763/Menstruation was described as a frequently reported time for disease-related pain among women and girls with sickle cell disease (SCD), and the report found that endorsement of menstrual-associated sickle cell pain was associated with higher acute care utilization over the prior six